Should Value Investors Buy Teladoc Health (TDOC) Stock?

31.12.24 15:40 Uhr

Werte in diesem Artikel
Aktien

9,27 EUR 0,32 EUR 3,53%

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.One company to watch right now is Teladoc Health (TDOC). TDOC is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A.Investors should also recognize that TDOC has a P/B ratio of 1.08. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. TDOC's current P/B looks attractive when compared to its industry's average P/B of 2.58. Over the past year, TDOC's P/B has been as high as 1.59 and as low as 0.72, with a median of 1.05.Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. TDOC has a P/S ratio of 0.62. This compares to its industry's average P/S of 1.22.Finally, investors should note that TDOC has a P/CF ratio of 8.03. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. TDOC's current P/CF looks attractive when compared to its industry's average P/CF of 19.28. Over the past year, TDOC's P/CF has been as high as 35.30 and as low as 6.26, with a median of 11.02.These are just a handful of the figures considered in Teladoc Health's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that TDOC is an impressive value stock right now.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Teladoc

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teladoc

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Teladoc Inc

Wer­bung

Analysen zu Teladoc Inc

DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
15.03.2018Teladoc HoldDeutsche Bank AG
28.02.2018Teladoc BuyChardan Capital Markets
DatumRatingAnalyst
02.11.2018Teladoc BuyChardan Capital Markets
03.08.2018Teladoc BuyChardan Capital Markets
05.06.2018Teladoc BuyCanaccord Adams
28.02.2018Teladoc BuyChardan Capital Markets
08.12.2017Teladoc BuyDeutsche Bank AG
DatumRatingAnalyst
15.03.2018Teladoc HoldDeutsche Bank AG
18.09.2017Teladoc NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teladoc Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"